PFIZER Aktie

 

Pfizer mRNA Influenza Vaccine 'Failed' In Clinical Trial Among Seniors: FDA Commissioner Authored by Zachary Stieber via The Epoch Times (emphasis ours), Pfizer's experimental influenza vaccine will not receive approval absent new data proving that it protects seniors against the flu, the commissioner of the Food and Drug Administration suggested in a new interview. A woman wears a facemask as she walks by the Pfizer world headquarters in New York City on Nov. 9, 2020. (Photo by Kena Betancur / AFP) Photo by KENA BETANCUR/AFP via Getty Images The messenger ribonucleic acid (mRNA) shot “failed in seniors,” Dr. Marty Makary, the FDA commissioner, said during an appearance on Nov. 29 on Fox News. “The trial showed zero benefit,” he said. “We're not just going to rubber-stamp new products that don't work, that fail in a clinical trial. It makes a mockery of science if we're just going to rubber-stamp things with no data.” Pfizer's media team did not respond to a request for comm...

Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum....

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store....

Pfizer kämpft seit dem Ende des pandemiebedingten Höhenflugs mit einem deutlichen Kursrückgang. Die während der COVID-Jahre erwirtschafteten Rekordmittel wurden nicht wie erhofft in nachhaltiges Wachstum überführt, und zahlreiche Investitionen rund um das Coronavirus erwiesen sich rückblickend als Fehleinschätzungen angesichts der kürzeren Pandemiedauer. Trotzdem ist die Aktie von Pfizer derzeit einer der am günstigsten bewerteten Titel […] The post Pfizer-Aktie: Darum bleibt sie ein Kauftipp! first appeared on sharedeals.de....

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants....

Merck & Co und Pfizer sind zwei absolute Schwergewichte in der Pharmabranche. Nur eine Aktie ist aber derzeit ein Kauf....

ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026....

Medicare Secures 71% Price Cut On Novo's Anti-Obesity Drug As Part Of Broad Affordability Push The Trump administration is laser-focused on "Operation Affordability," aiming to drive down the cost of food and healthcare ahead of the midterm election cycle. On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced a savings of 44%, or $12 billion, from last year's negotiated Medicare spending on 15 drugs used to treat severe chronic conditions and cancer.   Of those price cuts, CMS negotiated a 71% discount on GLP-1 medication, including Ozempic and Wegovy, for Medicare patients. Other significant reductions include a 50% cut for Pfizer's Ibrance, a 48% drop for the prostate-cancer drug Xtandi, and a 73% reduction for GSK's Trelegy Ellipta. Here's more from CMS:  The Maximum Fair Prices (MFPs) for these 15 drugs will become effective January 1, 2027, bringing the total number of negotiated drugs to 25 when combined with the 10 previously negotiated drugs with...

HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Pfizer auf "Hold" mit einem Kursziel von 25 US-Dollar belassen. Nach der jährlichen Branchenveranstaltung von Berenberg unter anderem mit Pfizer-Finanzchef Dave Denton sowie Informationsveranstaltungen ......

The weight loss drug market may approach almost $100 billion by the end of the decade....

Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer....

Escobar: The European Matryoshka Of Irrelevance Authored by Pepe Escobar, The EU/NATO combo cannot but play the role of pathetic yapping chihuahuas. That's the price you pay for a matrioshka of supreme stupidity. No one ever lost money betting on the politically suicidal instincts of post-Orwellian EU – that acronym for a virtual Europe. Call them juvenile bipolar psychos or a bunch of yapping chihuahuas: no Jupiterian or Mercurial voice of reason has been capable to impart to the “leadership” in Brussels and their vassals in most European capitals – yes, there are healthy exceptions – that losers in wars do not dictate terms. And still those War Council luminaries – with a special starring role for the toxic Pfizer Medusa and her Estonian sidekick unable to even manage a herring stall in the Baltics – insist that essentially the mega-corrupt gang in Kiev must prevail, to the last Ukrainian dead, and on top of it dictate the final terms of their non-surrender. Reality begs to di...

Byron Loflin, Nasdaq's Global Head of Board Advisory, and Mark Thompson, executive coach to leaders at Google, Apple and Pfizer, discuss their new book “CEO Ready,” including what makes an effective leader and the pros and cons of the co-CEO model. They speak with Romaine Bostick and Katie Greifeld on “The Close.” (Source: Bloomberg)...

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc. (NYSE: PFE) as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.* Ongoing studies are also evaluating vepdegestrant as a monotherapy and as part of combination therapy for ER+/HER2- breast cancer....

KENILWORTH (NJ) (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a N......

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains. read more...

Texas sues Sanofi and Bristol-Myers Squibb over alleged Plavix failures, as Paxton also finalizes a $41.5 million settlement with Pfizer and Tris over quality issues in children's medication. read more...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....

Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs....